Close Menu

NEW YORK — Prescient Metabiomics said on Tuesday that it has partnered with the Harvard TH Chan School of Public Health to investigate microbiome biomarkers in colon cancer.

Under the terms of the deal, Prescient Metabiomics and collaborators at the Harvard Chan Microbiome in Public Health Center will study the use of microbial biomarkers to identify precancerous adenomas and carcinomas in the colon. The effort will initially use bioinformatic approaches to analyze colorectal cancer cases across different populations, focusing on prevalent gut microbial biomarkers for the disease.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Jul
16
Sponsored by
NanoString

Join this webinar to learn how spatial resolution of gene expression in tumor tissue reveals new insights in biomarker discovery and therapeutic response. 

Jul
23
Sponsored by
Roche

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.

Jul
29
Sponsored by
Illumina

“If we build it, they will come” is a familiar refrain that echoes in life science entrepreneurial circles. Too frequently startups believe that if a technology is built it will sell.

Aug
25
Sponsored by
Roche

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.